Lucentis Articles
UK's NICE backs use of Novartis' Lucentis for diabetic macular edema
27 February 2013
Global orphan drugs market led by Roche's rituximab
26 February 2013
Scottish Medicines Consortium approves Eisai's Fycompa and Novartis' Lucentis for DME
11 December 2012
UK's NICE draft guidance backs NHS use of Lucentis in DME
5 October 2012
Trial and uptake of Regeneron's Eylea continues to rise among US retinal specialists; report
24 July 2012
Ophthotech's Fovista tops Lucentis in wet AMD
15 June 2012
Regeneron and Bayer’s Eylea backed by thought leaders for DME
13 February 2012
UK’s NICE unable to recommend Novartis Lucentis for diabetic macular edema; Fluvirin shipments begin in USA
18 July 2011
AMD and diabetic retinopathy drugs market to reach $5.08 billion by 2014, says Visiongain
11 July 2011
US FDA advisory panel nixes Roche’s Avastin for breast cancer; but good news on Lucentis in DME
30 June 2011
Good news for RVO suffers as EU approves Novartis’ Lucentis and NICE backs Allergan’s Ozurdex
6 June 2011
Second Lucentis Ph III study meets primary endpoint for improved vision in DME patients
28 March 2011
Ph III studies show Bayer and Regeneron VEGF Trap-Eye in wet AMD meets primary endpoints versus Lucentis
22 November 2010
PDL BioPharma sues Roche’s Genentech over royalties
2 September 2010
Roche 2009 figures miss targets, hit by Genentech buy costs and slowing sales of some cancer drugs
3 February 2010
Novartis posts 50% 4th-qtr 2009 profits rise and promotes drugs chief Jimenez to CEO; other top changes
26 January 2010
Novartis aims to hold global position in oncology, with new drugs and indications, R&D meeting told
9 December 2009
Roche nine-month 2009 sales boosted by strong Tamiflu showing
15 October 2009
PDL expects 18% rise in 2nd-qtr revenues
9 June 2009
PDL BioPharma swings to profit on cost-cuts
11 May 2009
Novartis' 1st-qtr 2009 results boosted by new products
24 April 2009
Stock Commentary - New York week to March 30, 2009
2 April 2009
Four Novartis drugs and B-MS
9 March 2009
Novartis will pay towards Lucentis in UK
1 September 2008
VEGF Trap-Eye enters Ph III testing
19 May 2008
Neovista's CABERNET trial to be expanded
28 April 2008
UK's NICE to finalize approval of Lucentis
7 April 2008
Xoma's 2007 loss falls 76% as sales soar 185%
24 March 2008
Elderly urged to change lifestyle to battle AMD
3 March 2008
UK NICE set for U-turn on Lucentis
17 December 2007
NeoVista enrolls first patient in EU trial of AMD radiotherapy
3 December 2007
Xoma posts $22M third quarter profit
19 November 2007
Genentech to curtail off-label Avastin use
22 October 2007
Alcon's Retaane gets FDA approvable letter
1 October 2007
Regeneron gets $20M milestone from Bayer
20 August 2007
Bayer/Regeneron begin Ph III Trap-Eye study
13 August 2007
NICE wet AMD drug rethink after 13,000 complaints
13 August 2007
UK charity to fund Lucentis court case
26 July 2007
Cancer, RA drugs boost Genentech
16 July 2007
UK's NICE "fails common sense test"
25 June 2007
Roche posts record 2006 net profits, boosted by cancer drugs
12 February 2007
EU clears Novartis' Lucentis for wet AMD
29 January 2007
Stock Commentary - New York week to Jan 15, 2007
22 January 2007
Genentech's 3rd-qtr GAAP net leaps 58%
16 October 2006
Novartis' Lucentis improves visual acuity in wet AMD, two pivotal Ph III studies find
16 October 2006
Biotech stocks in holding pattern for August, says Burrill report
18 September 2006
Switzerland first EU state to approve Novartis' Lucentis
4 September 2006
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
